Protocol Ledger

NCT05429632 · Phase III · RECRUITING

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Interventional Phase III clinical trial protocol NCT05429632 sponsored by Priothera SAS in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-16 Enrollment: 366 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05429632
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)366 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05429632
Protocol FieldVerified Registry Value
NCT IdentifierNCT05429632
Consolidated Lead SponsorPriothera SAS
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment366 participants (ESTIMATED)
Registered Start Date2022-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI